Molecular pathway ID’d as key driver of scarring in scleroderma
The molecular signaling pathway EGFR-STAT1 is key for driving fibrosis (scarring) in scleroderma, according to a new study. The findings suggest that treatments designed to inhibit this pathway could be used to help mitigate fibrosis in scleroderma and other disorders that are characterized by excessive scarring. The study, “…